Role of Kisspeptin-1 and Growth Differentiation Factor-15 in Iraqi Patients with Metastatic and Non-metastatic Colorectal Cancer

Sudad Salih Jawad; Zahraa Mohammed Ali

doi:10.54133/ajms.v8i2.1678

Authors

Sudad Salih Jawad Department of Pharmacy, Iraqi Ministry of Health, Baghdad, Iraq https://orcid.org/0009-0004-1504-5700
Zahraa Mohammed Ali Department of Clinical Lab Sciences, Collage of Pharmacy, University of Baghdad, Baghdad, Iraq https://orcid.org/0000-0001-5627-6215

DOI:

https://doi.org/10.54133/ajms.v8i2.1678

Keywords:

Carcinoembryonic antigen, Colorectal cancer, Growth differentiation factor-15, Kisspeptin-1

Abstract

Abstract

Background: Colorectal cancer (CRC) is a leading cause of cancer mortality worldwide. Identifying novel biomarkers is critical for improving diagnosis, prognosis, and treatment strategies. This study investigates the serum levels of kisspeptin-1 (KISS1), its receptor (KISS1R), growth differentiation factor 15 (GDF15), and carcinoembryonic antigen (CEA) in Iraqi CRC patients. Objectives: Explore associations between serum levels of Kiss1, Kiss1R, GDF, and CEA and disease progression in Iraqi patients with CRC. Methods: A case-control study was conducted, including 72 CRC patients and 36 healthy controls. Patients were stratified into non-metastatic and metastatic groups. Serum biomarker levels were measured using enzyme-linked immunosorbent assay (ELISA). Statistical analyses evaluated biomarker correlations, diagnostic accuracy, and associations with CRC stages. Results: Significant elevations of KISS1, KISS1R, GDF15, and CEA levels were observed in CRC patients compared to controls, with metastatic cases showing the highest levels. KISS1 and GDF15 demonstrated strong correlations and were particularly associated with metastatic disease. Receiver operating characteristic (ROC) analysis revealed high diagnostic accuracy for these biomarkers in distinguishing CRC stages. Conclusions: KISS1 and GDF15 are promising biomarkers for CRC progression and metastasis. Their coordinated elevation in metastatic cases suggests potential roles in disease monitoring and therapeutic targeting. Further studies are needed to confirm these findings and explore their clinical applications.

Downloads

Download data is not yet available.

References

Li LB, Wang LY, Chen DM, Liu YX, Zhang YH, Song WX, et al. A systematic analysis of the global and regional burden of colon and rectum cancer and the difference between early-and late-onset CRC from 1990 to 2019. Front Oncol. 2023;13:1102673. doi: 10.3389/fonc.2023.1102673. DOI: https://doi.org/10.3389/fonc.2023.1102673

Van Cutsem E, Cervantes A, Nordlinger B, Arnold D. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii1-9. doi: 10.1093/annonc/mdu260. DOI: https://doi.org/10.1093/annonc/mdu260

Sun J, Zhao J, Jiang F, Wang L, Xiao Q, Han F, et al. Identification of novel protein biomarkers and drug targets for colorectal cancer by integrating human plasma proteome with genome. Genome Med. 2023;15(1):75. doi: 10.1186/s13073-023-01188-5. DOI: https://doi.org/10.1186/s13073-023-01229-9

Cho SG, Li D, Tan K, Siwko SK, Liu M. KiSS1 and its G-protein-coupled receptor GPR54 in cancer development and metastasis. Cancer Metastasis Rev. 2012;31(3-4):585-591. doi: 10.1007/s10555-012-9376-0. DOI: https://doi.org/10.1007/s10555-012-9367-7

Ly T, Harihar S, Welch DR. KISS1 in metastatic cancer research and treatment: potential and paradoxes. Cancer Metastasis Rev. 2020;39(3):739-754. doi: 10.1007/s10555-020-09880-0. DOI: https://doi.org/10.1007/s10555-020-09868-9

Ciaramella V, Della Corte CM, Ciardiello F, Morgillo F. Kisspeptin and cancer: molecular interaction, biological functions, and future perspectives. Front Endocrinol (Lausanne). 2018;9:115. doi: 10.3389/fendo.2018.00115. DOI: https://doi.org/10.3389/fendo.2018.00115

Abbara A, Bhattacharya M. The versatile kisspeptin: advances in cancer, metabolism, and reproduction. Front Endocrinol (Lausanne). 2023;14:1239694. doi: 10.3389/fendo.2023.1239694. DOI: https://doi.org/10.3389/fendo.2023.1239694

Kostakis ID, Agrogiannis G, Vaiopoulos AG, Mylona E, Patsouris E, Kouraklis G, et al. A clinicopathological analysis of KISS1 and KISS1R expression in colorectal cancer. APMIS. 2015;123(7):629-637. doi: 10.1111/apm.12405. DOI: https://doi.org/10.1111/apm.12397

Zhou B, Huang WH, Chen S, Chen W, Peng P, Zhou Y, et al. GDF15 serves as a coactivator to enhance KISS1 gene transcription through interacting with Sp1. Carcinogenesis. 2021;42(2):294-302. doi: 10.1093/carcin/bgaa123.

Staff AC, Trovik J, Zahl EA, Wik E, Wollert KC, Kempf T, et al. Elevated plasma growth differentiation factor-15 correlates with lymph node metastases and poor survival in endometrial cancer. Clin Cancer Res. 2011;17(14):4825-4833. doi: 10.1158/1078-0432.CCR-11-0411. DOI: https://doi.org/10.1158/1078-0432.CCR-11-0715

Brown DA, Lindmark F, Stattin P, Bälter K, Adami HO, Zheng SL, et al. Macrophage inhibitory cytokine 1: a new prognostic marker in prostate cancer. Clin Cancer Res. 2009;15(21):6658-6664. doi: 10.1158/1078-0432.CCR-09-1366. DOI: https://doi.org/10.1158/1078-0432.CCR-08-3126

Wang X, Li Y, Tian H, Qi J, Li M, Fu C, et al. Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma. BMC Cancer. 2014;14:578. doi: 10.1186/1471-2407-14-578. DOI: https://doi.org/10.1186/1471-2407-14-578

Mehta RS, Song M, Bezawada N, Wu K, Garcia-Albeniz X, Morikawa T, et al. A prospective study of macrophage inhibitory cytokine-1 (MIC-1/GDF15) and risk of colorectal cancer. J Natl Cancer Inst. 2014;106(4):dju016. doi: 10.1093/jnci/dju016. DOI: https://doi.org/10.1093/jnci/dju016

Mehta RS, Chong DQ, Song M, Meyerhardt JA, Ng K, Nishihara R, et al. Association between plasma levels of macrophage inhibitory cytokine-1 before diagnosis of colorectal cancer and mortality. Gastroenterology. 2015;149(3):614-622. doi: 10.1053/j.gastro.2015.05.006. DOI: https://doi.org/10.1053/j.gastro.2015.05.038

Weiser MR. AJCC 8th edition: colorectal cancer. Ann Surg Oncol. 2018;25(6):1454-1455. doi: 10.1245/s10434-018-6462-1. DOI: https://doi.org/10.1245/s10434-018-6462-1

Li C, Wang X, Casal I, Wang J, Li P, Zhang W, et al. Growth differentiation factor 15 is a promising diagnostic and prognostic biomarker in colorectal cancer. J Cell Mol Med. 2016;20(8):1420-1426. doi: 10.1111/jcmm.12818. DOI: https://doi.org/10.1111/jcmm.12830

Kamel IF, Elsadek HM, Ahmad AM, Elagrody AI. Value of Serum Growth Differentiation Factor 15 in diagnosis of Colorectal Cancer. Egypt J Hosp Med. 2021;85(2):3639-3644. doi: 10.21608/ejhm.2021.191168. DOI: https://doi.org/10.21608/ejhm.2021.201980

Canbay E, Ergen A, Bugra D, Yamaner S, Eraltan IY, Buyukuncu Y, et al. Kisspeptin-54 levels are increased in patients with colorectal cancer. World J Surg. 2012;36(9):2218-2224. doi: 10.1007/s00268-012-1636-7. DOI: https://doi.org/10.1007/s00268-012-1636-7

Zhu C, Takasu C, Morine Y, Bando Y, Ikemoto T, Saito Y, et al. KISS1 associates with better outcome via inhibiting matrix metalloproteinase-9 in colorectal liver metastasis. Ann Surg Oncol. 2015;22(Suppl 3):1516-1523. doi: 10.1245/s10434-015-4891-7. DOI: https://doi.org/10.1245/s10434-015-4891-7

Spanopoulou A, Gkretsi V. Growth differentiation factor 15 (GDF15) in cancer cell metastasis: from the cells to the patients. Clin Exp Metastasis. 2020;37(4):451-464. doi: 10.1007/s10585-020-10050-0. DOI: https://doi.org/10.1007/s10585-020-10041-3

Zhou B, Huang WH, Chen S, Chen W, Peng P, Zhou Y, et al. GDF15 serves as a coactivator to enhance KISS-1 gene transcription through interacting with Sp1. Carcinogenesis. 2021;42(2):294-302. doi: 10.1093/carcin/bgaa116. DOI: https://doi.org/10.1093/carcin/bgaa103

Ji K, Ye L, Ruge F, Hargest R, Mason MD, Jiang WG. Implication of metastasis suppressor gene, Kiss-1 and its receptor Kiss-1R in colorectal cancer. BMC Cancer. 2014;14:723. doi: 10.1186/1471-2407-14-723. DOI: https://doi.org/10.1186/1471-2407-14-723